CÁNCER DE MAMA
Universidad Complutense de Madrid
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Universidad Complutense de Madrid (24)
2023
-
Germline gain-of-function MMP11 variant results in an aggressive form of colorectal cancer
International Journal of Cancer, Vol. 152, Núm. 2, pp. 283-297
-
Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer
Nature Communications, Vol. 14, Núm. 1
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
2022
-
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 6, pp. 1107-1116
-
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
Journal of Clinical Investigation, Vol. 132, Núm. 7
2021
-
C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells
Cell Death and Disease, Vol. 12, Núm. 4
-
C3G protein, a new player in glioblastoma
International Journal of Molecular Sciences, Vol. 22, Núm. 18
-
HGK promotes metastatic dissemination in prostate cancer
Scientific Reports, Vol. 11, Núm. 1
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
-
The pseudokinase TRIB3 negatively regulates the HER2 receptor pathway and is a biomarker of good prognosis in luminal breast cancer
Cancers, Vol. 13, Núm. 21
2020
-
C3G is upregulated in hepatocarcinoma, contributing to tumor growth and progression and to HGF/MET pathway activation
Cancers, Vol. 12, Núm. 8, pp. 1-22
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study
Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
2018
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
2017
2016
-
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89
2015
-
SEOM clinical guidelines in metastatic breast cancer 2015
Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 946-955